GSK3B and cancer: Considering the ambiguous role of GSK3β activity in cancer, the fact that AZD5363 allows sensitization to doxorubicin while relieving GSK3β of inhibitory post‐translational modification allows us to surmise that, in our context, this kinase acts as a tumor suppressor.